002422 Share Price Performance
CN¥0
-27.43 (-100.00%)
Price CN¥0
Fair ValueCN¥30.00
Share Pricen/a
Sichuan Kelun Pharmaceutical Co., Ltd. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
002422 Community Narratives
AN
Fair Value CN¥30 11.5% overvalued intrinsic discount
International Regulatory Hurdles And China Pricing Pressure Will Erode Margins
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value CN¥40.31 17.0% undervalued intrinsic discount
002422: Rising Profit Margins and Cash Dividend Will Drive Positive Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value CN¥46 27.3% undervalued intrinsic discount
Rising Middle Class And Aging Populations Will Expand Drug Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
International Regulatory Hurdles And China Pricing Pressure Will Erode Margins
Key Takeaways Growing pricing pressure, regulatory uncertainties, and rising compliance costs threaten future sales growth, profitability, and international revenue potential. Heavy R&D spending, reliance on legacy products, and tightening ESG requirements may erode market share and strain operational margins over time.Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
CN¥30
11.5% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
8.69% p.a.
Profit Margin
12.27%
Future PE
21.98x
Price in 2028
CN¥36.49
002422: Rising Profit Margins and Cash Dividend Will Drive Positive Outlook
Key Takeaways Expanding innovative drug pipeline and commercial launches, underpinned by rapid insurance uptake, drive strong growth in recurrent and high-visibility revenues. International partnerships and broad innovation investments enhance earnings potential, margin expansion, and global market presence.Read more
26
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CN¥40.31
17.0% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
10.76% p.a.
Profit Margin
14.84%
Future PE
23.07x
Price in 2028
CN¥49.03
Rising Middle Class And Aging Populations Will Expand Drug Markets
Key Takeaways Accelerated new therapy launches, global partnerships, and innovative drug focus could drive earnings growth and margin expansion beyond current expectations. Expanding domestic reach and overseas market entry, coupled with policy agility and strong financials, may unlock sustained revenue growth and defensible earnings.Read more
8
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CN¥46
27.3% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
15.18% p.a.
Profit Margin
15.29%
Future PE
20.44x
Price in 2028
CN¥55.83
Trending Discussion
Recently Updated Narratives
AN
002422: Fair Value Will Reflect Higher Sales Outlook And Softer Margins
Fair Value: CN¥30 11.5% overvalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
002422: Interim Dividend Will Support Future Returns Despite Slight Margin Headwinds
Fair Value: CN¥40.31 17.0% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising Middle Class And Aging Populations Will Expand Drug Markets
Fair Value: CN¥46 27.3% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Sichuan Kelun Pharmaceutical Co., Ltd. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Apr 03, 2026
- 1.05
- 47.77%
- 9.10%
- 12.5%
About 002422
- Founded
- 1996
- Employees
- 21864
- CEO
- WebsiteView website
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. It operates through Twinings, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumor, anti-emetic, antibiotic, VB12, anti-rheumatoid arthritis, multiple sclerosis, anti-schizophrenia, CKD and anti-anemia, polypeptide, and other indications. It also provides ambroxol hydrochloride, potassium chloride, sodium chloride, magnesium sulfate, glucose, sterile water, sodium bicarbonate, lidocaine hydrochloride, vitamin B6, ribavirin, ceftazidime, 5% glucose, and ceftriaxone sodium injections. In addition, the company engages in investment; import and export; enterprise management; logistics and transportation; business services; agricultural non-staple food processing; production and sale of pharmaceutical intermediates; research and development of bio-based materials technology; Internet and related services; crop cultivation; professional technical; biotechnology extension; socioeconomic counseling; technical promotion and application; medical research and testing exhibition; general cargo road transport; ecological protection and environmental management; scientific research and technical service; and western medicine wholesale activities. It exports its products to Japan. The company was formerly known as Sichuan Kelun Pharmaceutical Factory Co., Ltd and changed its name to Sichuan Kelun Pharmaceutical Co., Ltd. in August 2003. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Industry Group CO., LTD.
